Ristau Jonas, Hörner-Rieber Juliane, Körber Stefan A
Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
J Gastrointest Oncol. 2024 Aug 31;15(4):1893-1907. doi: 10.21037/jgo-22-961. Epub 2023 Sep 1.
Magnetic resonance guided radiotherapy (MRgRT) is an emerging technological innovation with more and more institutions gaining clinical experience in this new field of radiation oncology. The ability to better visualize both tumors and healthy tissues due to excellent soft tissue contrast combined with new possibilities regarding motion management and the capability of online adaptive radiotherapy might increase tumor control rates while potentially reducing the risk of radiation-induced toxicities. As conventional computed tomography (CT)-based image guidance methods are insufficient for adaptive workflows in abdominal tumors, MRgRT appears to be an optimal method for this tumor site. The aim of this narrative review is to outline the opportunities and challenges in magnetic resonance guided radiation therapy in gastrointestinal cancers.
We searched for studies, reviews and conceptual articles, including the general technique of MRgRT and the specific utilization in gastrointestinal cancers, focusing on pancreatic cancer, liver metastases and primary liver cancer, rectal cancer and esophageal cancer.
This review is highlighting the innovative approach of MRgRT in gastrointestinal cancer and gives an overview of the currently available literature with regard to clinical experiences and theoretical background.
MRgRT is a promising new tool in radiation oncology, which can play off several of its beneficial features in the specific field of gastrointestinal cancers. However, clinical data is still scarce. Nevertheless, the available literature points out large potential for improvements regarding dose coverage and escalation as well as the reduction of dose exposure to critical organs at risk (OAR). Further prospective studies are needed to demonstrate the role of this innovative technology in gastrointestinal cancer management, in particular trials that randomly compare MRgRT with conventional CT-based image-guided radiotherapy (IGRT) would be of high value.
磁共振引导放疗(MRgRT)是一项新兴的技术创新,越来越多的机构在这一放射肿瘤学新领域积累了临床经验。由于其出色的软组织对比度,能够更好地可视化肿瘤和健康组织,同时结合运动管理的新可能性以及在线自适应放疗的能力,可能会提高肿瘤控制率,同时潜在地降低放射诱导毒性的风险。由于基于传统计算机断层扫描(CT)的图像引导方法不足以用于腹部肿瘤的自适应工作流程,MRgRT似乎是该肿瘤部位的最佳方法。本叙述性综述的目的是概述磁共振引导放疗在胃肠道癌中的机遇与挑战。
我们检索了研究、综述和概念性文章,包括MRgRT的一般技术以及在胃肠道癌中的具体应用,重点关注胰腺癌、肝转移瘤和原发性肝癌、直肠癌和食管癌。
本综述强调了MRgRT在胃肠道癌中的创新方法,并概述了目前关于临床经验和理论背景的可用文献。
MRgRT是放射肿瘤学中一种有前景的新工具,它可以在胃肠道癌的特定领域发挥其若干有益特性。然而,临床数据仍然匮乏。尽管如此,现有文献指出在剂量覆盖和递增以及减少对危险关键器官(OAR)的剂量暴露方面有很大的改进潜力。需要进一步的前瞻性研究来证明这项创新技术在胃肠道癌管理中的作用,特别是将MRgRT与传统基于CT的图像引导放疗(IGRT)进行随机比较的试验将具有很高的价值。